TMT1B and neoplasm: TMT1B has been proposed as a biomarker for many of these cancers since its increased transcription and protein abundance is frequently correlated with an advanced TNM (Tumour, Node, Metastasis) stage of tumour development and poor patient overall survival (21–27, 29, 31–36), risk of recurrence (35) and drug resistance (16, 37).